

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 January 2022 (13.01.2022)



(10) International Publication Number
WO 2022/011083 A1

(51) International Patent Classification:

C07D 231/44 (2006.01) C07D 451/02 (2006.01)
C07D 401/04 (2006.01) C07D 487/08 (2006.01)
C07D 401/14 (2006.01) C07D 491/10 (2006.01)
C07D 403/04 (2006.01) A61P 9/00 (2006.01)
C07D 407/14 (2006.01) A61P 11/00 (2006.01)
C07D 413/06 (2006.01) A61K 31/4152 (2006.01)
C07D 413/14 (2006.01)

(21) International Application Number:

PCT/US2021/040793

(22) International Filing Date:

08 July 2021 (08.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/049,831 09 July 2020 (09.07.2020) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**
[US/US]; Route 206 and Province line Road, Princeton,
New Jersey 08543 (US).

(72) Inventors: **JOHNSON, James A.**; c/o Bristol-Myers
Squibb Company, Route 206 and Province Line Road,
Princeton, New Jersey 08543 (US). **PI, Zulan**; c/o Bris-
tol-Myers Squibb Company, Route 206 and Province
Line Road, Princeton, New Jersey 08543 (US). **WURTZ,**
Nicholas R.; c/o Bristol-Myers Squibb Company, Route
206 and Province Line Road, Princeton, New Jersey 08543
(US). **SMALLHEER, Joanne M.**; 1101 West Skyview
Landings Drive, Hernando, Florida 34442 (US). **VA-**
LENTE, Meriah Neissel; c/o Bristol-Myers Squibb Com-
pany, Route 206 and Province Line Road, Princeton, New
Jersey 08543 (US). **KICK, Ellen K.**; c/o Bristol-Myers
Squibb Company, Route 206 and Province Line Road,
Princeton, New Jersey 08543 (US). **CLARK, Charles G.**;
4 Glenview Place, Cherry Hill, New Jersey 08034 (US).
SHIRUDE, Pravin Sudhakar; c/o Syngene International
Limited, Biocon Special Economic Zone, Plot Nos. 2&3
Bommasandra IV Phase, Jigani Link Road, Bommasandra,
Bangalore 560 099 (IN). **SESHADRI, Balaji**; c/o Syngene
International Limited, Biocon Special Economic Zone, Plot
Nos. 2&3 Bommasandra IV Phase, Jigani Link Road, Bom-
masandra, Bangalore 560 099 (IN). **CHATTOPADHYAY,**
Amit Kumar; c/o Syngene International Limited, Biocon

Special Economic Zone, Plot Nos. 2&3 Bommasandra IV
Phase, Jigani Link Road, Bommasandra, Bangalore 560 099
(IN).

(74) Agent: **LIU, Hong** et al.; Bristol-Myers Squibb Company,
Route 206 and Province Line Road, Princeton, New Jersey
08543 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS



(57) Abstract: The disclosure relates to compounds of formula I, which are formyl peptide 2 (FPR2) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

WO 2022/011083 A1